Document

DEF 14A 1 a2022proxydef14a.htm DEF 14A Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

________________________________________________________________

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

________________________________________________________________

Filed by the Registrant x Filed by a party other than the Registrant o


Check the appropriate box:
o						Preliminary Proxy Statement
o						Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
x						Definitive Proxy Statement
o						Definitive Additional Materials
o						Soliciting Material Pursuant to §240.14a-12

Surgery Partners, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):


x	No fee required.

o	Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

	(1)	Title of each class of securities to which transaction applies:

	(2)	Aggregate number of securities to which transaction applies:

	(3)	Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

	(4)	Proposed maximum aggregate value of transaction:

	(5)	Total fee paid:


o	Fee paid previously with preliminary materials.

o	Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

	(1)	Amount previously paid:

	(2)	Form, Schedule or Registration Statement No:

	(3)	Filing party:

	(4)	Date Filed:

April 7, 2022

TO OUR STOCKHOLDERS:

You are cordially invited to attend the 2022 annual meeting of stockholders of Surgery Partners, Inc., to be held on May 19, 2022, at 8:00 a.m. (Central Daylight Time), at our corporate headquarters located at 310 Seven Springs Way, Suite 500, Brentwood, Tennessee 37027.

Although we intend to hold the annual meeting in person, we are actively monitoring the COVID-19 pandemic as part of our effort to maintain a healthy and safe environment at the annual meeting. In the event it is not possible or advisable to hold the annual meeting in person, we will announce alternative arrangements for the meeting as promptly as practicable, which may include holding the meeting solely by means of remote communication. If we take this step, details on how to participate will be issued by press release, posted on our website and filed with the Securities and Exchange Commission (the "SEC").

In accordance with rules adopted by the SEC, we are mailing to many of our stockholders a Notice of Internet Availability of Proxy Materials instead of a paper copy of the Proxy Statement, the proxy card and our Annual Report to Stockholders. The Notice of Internet Availability of Proxy Materials contains instructions on how stockholders can access the proxy materials over the internet as well as request a paper or email copy if desired.

It is important that your shares be represented at the annual meeting. Whether or not you plan to attend the annual meeting, we would greatly appreciate your efforts to vote your shares as soon as possible by following the instructions located in the Notice of Internet Availability of Proxy Materials or in our proxy statement. If you attend the annual meeting and wish to vote at that time, you may withdraw your proxy and vote your shares personally.

Sincerely,

/s/ Wayne S. DeVeydt

Wayne S. DeVeydt

Executive Chairman of the Board of Directors

NOTICE OF ANNUAL MEETING OF STOCKHOLDERS

APRIL 7, 2022

DATE: May 19, 2022

TIME: 8:00 a.m. CDT

PLACE: Corporate Headquarters (principal executive office)

310 Seven Springs Way, Suite 500

Brentwood, Tennessee 37027

ITEMS OF BUSINESS:

1.To elect the three Class I director nominees named in this Proxy Statement to the Board of Directors of Surgery Partners, Inc. (the "Company") for a term of three years;

2.To approve, on an advisory basis, the compensation paid by the Company to its named executive officers;

3.To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2022; and

4.To consider and act upon any other business that may properly come before the 2022 annual meeting of stockholders and at any adjournment or postponement thereof.

Information relating to the matters to be considered and voted on at the annual meeting is set forth in the enclosed proxy materials.

RECORD DATE: Holders of shares of our common stock of record at the close of business on March 30, 2022 are entitled to receive notice of and vote at the annual meeting and at any adjournment or postponement thereof.

ANNUAL REPORT: The Company's Annual Report to Stockholders for the fiscal year ended December 31, 2021, which is not part of the proxy soliciting materials, is available to you on the internet or, upon request, will be delivered to you by mail or email.

PROXY VOTING: It is important that your shares be represented and voted at the meeting. You can vote your shares by phone or online, or if you request a printed copy, by completing and returning the proxy card sent to you. You can revoke a proxy at any time prior to its exercise at the annual meeting by following the instructions in the attached Proxy Statement. If you decide to attend the annual meeting and wish to change your proxy, you may do so by voting during the meeting.

YOUR VOTE IS IMPORTANT. WHETHER OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETING, AFTER REVIEWING THE PROXY MATERIALS, PLEASE VOTE BY PHONE OR ONLINE BY FOLLOWING THE INSTRUCTIONS SET FORTH IN THE FOLLOWING PROXY MATERIALS, OR IF YOU REQUESTED A PRINTED COPY, PLEASE COMPLETE, DATE, SIGN AND RETURN THE PROXY CARD IN THE ENCLOSED STAMPED ENVELOPE.

The Board of Directors unanimously recommends that you vote: (i) "FOR" the election of the three Class I director nominees named in the Proxy Statement, (ii) "FOR" the approval, on an advisory basis, of the compensation paid by the Company to its named executive officers, and (iii) "FOR" ratification of the Audit Committee’s appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm.

You are welcome to attend the annual meeting. However, even if you plan to attend, please vote your shares promptly to ensure they are represented at the annual meeting. If you decide to attend the annual meeting and wish to change your proxy, you may do so by

voting in person at the meeting. To obtain directions to attend the annual meeting and vote in person, please contact Investor Relations at 310 Seven Springs Way, Suite 500, Brentwood, Tennessee 37027, (615) 234-5900 or email ir@surgerypartners.com.

Thank you for your ongoing support of and interest in Surgery Partners, Inc.

By Order of the Board of Directors,

/s/ Wayne S. DeVeydt

Wayne S. DeVeydt

Executive Chairman of the Board of Directors

Brentwood, Tennessee

April 7, 2022

IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 19, 2022:

THE PROXY STATEMENT, THE PROXY CARD AND OUR ANNUAL REPORT TO STOCKHOLDERS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 ARE AVAILABLE TO YOU ON THE INTERNET OR, UPON YOUR REQUEST WILL BE DELIVERED TO YOU BY MAIL OR EMAIL, IN CONNECTION WITH THE SOLICITATION OF PROXIES BY THE BOARD OF DIRECTORS OF THE COMPANY TO BE VOTED ON AT THE ANNUAL MEETING. THE NOTICE OF INTERNET AVAILABILITY OF PROXY MATERIALS IS SCHEDULED TO BE DISTRIBUTED ON OR ABOUT APRIL 7, 2022 TO STOCKHOLDERS OF RECORD AS OF THE CLOSE OF BUSINESS ON MARCH 30, 2022.

THE PROXY STATEMENT, THE PROXY CARD AND OUR ANNUAL REPORT TO STOCKHOLDERS FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 ARE AVAILABLE ON THE INTERNET AT WWW.INVESTORVOTE.COM/SGRY.

TABLE OF CONTENTS


			Page

IMPORTANT INFORMATION ABOUT THE ANNUAL MEETING AND VOTING			1
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT			5
PROPOSAL NO. 1: ELECTION OF DIRECTORS			7
CORPORATE GOVERNANCE			10
PROPOSAL NO. 2: ADVISORY VOTE ON EXECUTIVE COMPENSATION			15
EXECUTIVE OFFICERS			16
COMPENSATION DISCUSSION AND ANALYSIS			18
REPORT OF THE COMPENSATION COMMITTEE			28
EXECUTIVE COMPENSATION			29
DIRECTOR COMPENSATION			41
PROPOSAL NO. 3: RATIFICATION OF THE AUDIT COMMITTEE'S APPOINTMENT OF THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM			42
FEES PAID TO INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM			43
REPORT OF THE AUDIT COMMITTEE			44
EQUITY COMPENSATION PLANS			45
RELATED PERSON TRANSACTIONS			46
GENERAL MATTERS			46


Name of Beneficial Owner	Number of Shares of Common Stock Beneficially Owned	Percentage of Common Stock Beneficially Owned

Beneficial owners of 5% or more of our common stock:
BCPE Seminole Holdings LP (1)(2)	49,064,576	54.6	%
FMR LLC (3)	10,474,372	11.7	%
Directors and Named Executive Officers:
Brent Turner (4)	47,686	*
Teresa DeLuca, M.D.	23,938	*
Andrew T. Kaplan (5)	—	—
T. Devin O'Reilly (5)	—	—
Blair E. Hendrix (5)	—	—
John A. Deane	12,999	*
Clifford G. Adlerz	36,181	*
Patricia A. Maryland, Dr.PH	3,330	*
Wayne S. DeVeydt (6)	1,145,256	1.3	%
J. Eric Evans (7)	742,671	*
Thomas F. Cowhey	180,136	*
Jennifer B. Baldock (8)	274,849	*
Anthony W. Taparo (9)	198,169	*
Bradley R. Owens	77,780	*
All executive officers and directors as a group (18 persons) (10)	3,007,982	3.3	%


Name	Age	Position
John A. Deane	60	Class I Director
Teresa DeLuca, M.D.	56	Class I Director
Wayne S. DeVeydt	52	Class I Director, Chairman
Patricia A. Maryland, Dr.PH	68	Class II Director
T. Devin O'Reilly	47	Class II Director
Brent Turner	56	Class II Director
Clifford G. Adlerz	68	Class III Director
J. Eric Evans	45	Class III Director
Blair E. Hendrix	57	Class III Director
Andrew T. Kaplan	37	Class III Director


Named Executive Officer			Title
J. Eric Evans			Chief Executive Officer
Thomas F. Cowhey (1)			Former Executive Vice President and Chief Financial Officer (1)
Jennifer B. Baldock			Executive Vice President, Chief Administrative and Development Officer
Anthony W. Taparo			Chief Growth Officer
Bradley R. Owens			President, National Group


Acadia Healthcare Company, Inc.	Hanger	Mednax, Inc.
Amedisys, Inc.	Chemed Corporation	Brookdale Senior Living
Encompass Health (formerly HealthSouth Corporation)	LHC Group, Inc.	The Ensign Group, Inc.
Genesis Healthcare	Tivity Health	RadNet, Inc.
ModivCare (formerly The Providence Service Corp)	Select Medical Holdings Corp


Named Executive Officer	2020 Base Salary (1)	2021 Base Salary
J. Eric Evans	$1,050,000	$1,050,000
Thomas F. Cowhey	500,000	525,000
Jennifer B. Baldock	420,000	420,000
Anthony W. Taparo	410,000	410,000
Bradley R. Owens (2)	N/A	400,000


2021 Cash Incentive Plan Performance Goals	Threshold	Target	Above Target	Maximum
Adjusted EBITDA (in millions)	$299.0	$315.0	$323.0	$331.0
Payout	25%	100%	150%	200%


Named Executive Officer			2021 Cash Incentive Award Earned
J. Eric Evans			$750,000
Thomas F. Cowhey (1)			N/A
Jennifer B. Baldock			452,000
Anthony W. Taparo			326,440
Bradley R. Owens			390,000


Named Executive Officer			2022 Short-Term Incentive Award Target
J. Eric Evans			$1,050,000
Thomas F. Cowhey (1)			N/A
Jennifer B. Baldock			425,000
Anthony W. Taparo			270,000
Bradley R. Owens			300,000


Named Executive Officer	Time-based restricted stock		PSUs (at Target)
	$ value	# shares of common stock	$ value	# units of common stock
J. Eric Evans	625,000	14,866	625,000	14,866
Thomas F. Cowhey	262,500	6,244	262,500	6,244
Jennifer B. Baldock	225,000	5,352	225,000	5,352
Anthony W. Taparo	205,000	4,876	205,000	4,876
Bradley R. Owens	200,000	4,757	200,000	4,757


Name and Principal Position	Year	Salary	Bonus	Stock Awards(5)(6)	Option Awards(7)	Non-Equity Incentive Plan Compensation (8)	Change in Pension Value and Nonqualified Deferred Compensation Earnings	All Other Compensation (9)	Total
J. Eric Evans Chief Executive Officer	2021	1,050,000	—	2,500,000	—	750,000	—	7,123	4,307,123
	2020	915,963	—	2,250,000	—	375,000	—	900	3,541,863
	2019	435,157	300,000(4)	1,382,500	2,526,598	—	—	675	4,644,930
Thomas F. Cowhey Former Executive Vice President and Chief Financial Officer (1)	2021	519,231	—	1,037,500	—	393,750	—	7,700	1,958,181
	2020	481,581	—	937,500	—	187,500	—	3,323	1,609,904
	2019	469,030	—	500,000	1,632,464	286,875	—	900	2,889,269
Jennifer B. Baldock Executive Vice President, Chief Administrative and Development Officer	2021	420,000	—	600,000	—	452,000	34,036	16,100	1,522,136
	2020	411,097	—	576,000	—	126,000	18,963	14,600	1,146,659
	2019	440,481	—	450,000	766,372	170,000	27,991	14,500	1,869,343
Anthony W. Taparo Chief Growth Officer (2)	2021	410,000	—	410,000	—	326,440	133,218	15,400	1,295,058
	2020	404,230	—	533,000	—	123,000	76,749	13,577	1,150,556
Bradley R. Owens President, National Group (3)	2021	391,923	—	600,000	—	390,000	—	6,800	1,388,723


	Stock Awards
Name	Number of Shares Acquired on Vesting (#)	Value Realized on Vesting
J. Eric Evans	28,885 (5)	1,278,450
	32,603 (6)	1,371,282
	8,571 (7)	374,981
Thomas F. Cowhey	4,917 (2)	214,381
	6,209 (3)	261,151
	9,314 (4)	391,747
	13,041 (6)	548,504
	4,285 (7)	187,469
Jennifer B. Baldock	4,375 (1)	190,356
	5,588 (3)	235,031
	8,383 (4)	352,589
	11,737 (6)	493,658
	2,880 (7)	126,000
Anthony W. Taparo	3,402 (1)	148,021
	4,346 (3)	182,793
	6,520 (4)	274,231
	10,693 (6)	449,748
	2,811 (7)	122,981
Bradley R. Owens	9,520 (6)	400,411
	2,085 (7)	91,219


Name	Benefit	Death/Disability	Termination Without Cause / Resignation for Good Reason	Termination Without Cause / Resignation for Good Reason In Connection with a Change in Control
J. Eric Evans	Cash Severance (1)	$—	$1,800,000	$1,800,000
	Equity Payout / Acceleration	11,837,365 (3)	6,978,389 (4)	18,815,754 (6)
	Health Benefits (2)	—	18,318	18,318
Thomas F. Cowhey	Cash Severance (1)	—	918,750	918,750
	Equity Payout / Acceleration	4,963,765 (3)	7,970,838 (5)	10,342,500 (6)
	Health Benefits (2)	—	18,496	18,496
Jennifer B. Baldock	Cash Severance (1)	—	672,000	672,000
	Equity Payout / Acceleration	4,357,081 (3)	5,163,423 (5)	7,016,456 (6)
	Health Benefits (2)	—	24,751	24,751
Anthony W. Taparo	Cash Severance (1)	—	656,000	656,000
	Equity Payout / Acceleration	3,696,666 (3)	4,074,664 (5)	5,676,171 (6)
	Health Benefits (2)	—	8,047	8,047
Bradley R. Owens	Cash Severance (1)	—	640,000	640,000
	Equity Payout / Acceleration	3,050,459 (3)	1,482,884 (5)	3,050,459 (6)
	Health Benefits (2)	—	—	—


Name	2021 PSU Awards	2020 PSU Awards	2019 PSU Awards
J. Eric Evans	1,875,000	1,875,000	—
Thomas F. Cowhey	787,500	750,000	374,982
Jennifer B. Baldock	450,000	450,000	337,500
Anthony W. Taparo	410,000	410,000	—
Bradley R. Owens	400,000	—	—


Name	Year	Company 401(k) match contributions (a)	Company contributions under the SERP (b)	Other (c)	Total
J. Eric Evans	2021	5,800	—	1,323	7,123
	2020	—	—	900	900
	2019	—	—	675	675
Thomas F. Cowhey	2021	5,800	—	1,900	7,700
	2020	2,423	—	900	3,323
	2019	—	—	900	900
Jennifer B. Baldock	2021	5,800	8,400	1,900	16,100
	2020	5,700	8,000	900	14,600
	2019	5,600	8,000	900	14,500
Anthony W. Taparo	2021	5,800	8,200	1,400	15,400
	2020	4,677	8,000	900	13,577
Bradley R. Owens	2021	5,800	—	1,000	6,800


			Estimated Future Payouts Under Non-Equity Incentive Plan Awards(1)			Estimated Future Payouts Under Equity Incentive Plan Awards			All other stock awards: Number of shares of stock (# of shares)	Grant Date fair value of stock and option awards
Name	Type of Award	Grant Date	Threshold	Target	Maximum	Threshold (# of shares)	Target (# of shares)	Maximum (# of shares)
J. Eric Evans	Cash Incentive	—	187,500	750,000	1,500,000	—	—	—	—	—
	Restricted Stock (2)	3/10/21	—	—	—	—	—	—	14,866	625,000 (7)
	Restricted Stock (6)	3/10/21	—	—	—	—	—	—	14,866	625,000 (7)
	PSUs (3)	3/10/21	—	—	—	3,717	14,866	29,732	—	625,000 (8)
	PSUs (4)	3/10/21	—	—	—	—	14,866	—	—	625,000 (8)
	Unrestricted Stock (5)	3/26/21	—	—	—	—	—	—	8,571	375,000
Thomas F. Cowhey	Cash Incentive	—	98,438	393,750	787,500	—	—	—	—	—
	Restricted Stock (2)	3/10/21	—	—	—	—	—	—	6,244	262,500 (7)
	Restricted Stock (6)	3/10/21	—	—	—	—	—	—	5,946	250,000 (7)
	PSUs (3)	3/10/21	—	—	—	1,561	6,244	12,488	—	262,500 (8)
	PSUs (4)	3/10/21	—	—	—	—	6,244	—	—	262,500 (8)
	Unrestricted Stock (5)	3/26/21	—	—	—	—	—	—	4,285	187,500
Jennifer B. Baldock	Cash Incentive	—	63,000	252,000	504,000	—	—	—	—	—
	Restricted Stock (2)	3/10/21	—	—	—	—	—	—	5,352	225,000 (7)
	Restricted Stock (6)	3/10/21	—	—	—	—	—	—	3,568	150,000 (7)
	PSUs (3)	3/10/21	—	—	—	1,338	5,352	10,704	—	225,000 (8)
	Unrestricted Stock (5)	3/26/21	—	—	—	—	—	—	2,880	126,000
Anthony W. Taparo	Cash Incentive	—	61,500	246,000	492,000	—	—	—	—	—
	Restricted Stock (6)	3/10/21	—	—	—	—	—	—	4,876	205,000 (7)
	PSUs (3)	3/10/21	—	—	—	1,219	4,876	9,752	—	205,000 (8)
	Unrestricted Stock (5)	3/26/21	—	—	—	—	—	—	2,811	123,000
Bradley R. Owens	Cash Incentive	—	60,000	240,000	480,000	—	—	—	—	—
	Restricted Stock (2)	3/10/21	—	—	—	—	—	—	4,757	200,000 (7)
	Restricted Stock (6)	3/10/21	—	—	—	—	—	—	4,757	200,000 (7)
	PSUs (3)	3/10/21	—	—	—	1,189	4,757	9,514	—	200,000 (8)
	Unrestricted Stock (5)	3/26/21	—	—	—	—	—	—	2,085	91,250


	Option Awards				Stock Awards
Name	Number of Securities Underlying Unexercised Options (#) Exercisable	Number of Securities Underlying Unexercised Options (#) Unexercisable	Option Exercise Price	Option Expiration Date	Number of shares or units of stock that have not vested (#)	Market value of shares or units of stock that have not vested (12)	Equity Incentive Plan Awards: Number of unearned shares, units or other rights that have not yet vested (#)	Equity Incentive Plan Awards: Market or payout value of unearned shares, units or other rights that have not yet vested (12)
J. Eric Evans	333,332 (1)	166,668 (1)	11.54	4/1/2029	—	—	—	—
	—	—	—	—	28,885 (3)	1,542,748	—	—
	—	—	—	—	65,206 (6)	3,482,652	—	—
	—	—	—	—	97,809 (7)	5,223,979	—	—
	—	—	—	—	14,866 (8)	793,993	—	—
	—	—	—	—	14,866 (9)	793,993	—	—
	—	—	—	—	—	—	14,866 (10)	793,993
	—	—	—	—	—	—	14,866 (11)	793,993
Thomas F. Cowhey	268,998 (2)	134,502 (2)	13.42	3/15/2029	—	—	—	—
	—	—	—	—	6,210 (4)	331,676	—	—
	—	—	—	—	9,314 (5)	497,461	—	—
	—	—	—	—	26,082 (6)	1,393,040	—	—
	—	—	—	—	39,123 (7)	2,089,559	—	—
	—	—	—	—	6,244 (8)	333,492	—	—
	—	—	—	—	5,964 (9)	318,537	—	—
	—	—	—	—	—	—	6,244 (10)	333,492
	—	—	—	—	—	—	6,244 (11)	333,492
Jennifer B. Baldock	132,999 (2)	66,501 (2)	13.42	3/15/2029	—	—	—	—
	—	—	—	—	5,590 (4)	298,562	—	—
	—	—	—	—	8,383 (5)	447,736	—	—
	—	—	—	—	23,474 (6)	1,253,746	—	—
	—	—	—	—	35,211 (7)	1,880,620	—	—
	—	—	—	—	5,352 (8)	285,850	—	—
	—	—	—	—	3,568 (9)	190,567	—	—
	—	—	—	—	—	—	5,352 (10)	285,850
Anthony W. Taparo	99,000 (2)	49,500 (2)	13.42	3/15/2029	—	—	—	—
	—	—	—	—	4,348 (4)	232,227	—	—
	—	—	—	—	6,520 (5)	348,233	—	—
	—	—	—	—	21,388 (6)	1,142,333	—	—
	—	—	—	—	32,081 (7)	1,713,446	—	—
	—	—	—	—	4,876 (8)	260,427	—	—
	—	—	—	—	—	—	4,876 (10)	260,427
Bradley R. Owens	—	—	—	—	19,040 (6)	1,016,926	—	—
	—	—	—	—	28,560 (7)	1,525,390	—	—
	—	—	—	—	4,757 (8)	254,071	—	—
	—	—	—	—	4,757 (9)	254,071	—	—
	—	—	—	—	—	—	4,757 (10)	254,071


Name	Executive contributions in last fiscal year (1)	Company contributions in last fiscal year (2)	Aggregate earnings in last fiscal year (3)	Aggregate withdrawals/ distributions	Aggregate balance at last fiscal year end
J. Eric Evans	—	—	—	—	—
Thomas F. Cowhey	—	—	—	—	—
Jennifer B. Baldock	10,920	8,400	34,036	—	217,300
Anthony W. Taparo	24,600	8,200	133,218	—	704,071
Bradley R. Owens	—	—	—	—	—


Name	Fees Earned or Paid in Cash	Stock Awards(4)	Total
Wayne S. DeVeydt (1)	$500,000	$250,000	$750,000
Brent Turner	95,000	140,000	235,000
Teresa DeLuca, M.D.	90,000	140,000	230,000
John A. Deane	75,000	140,000	215,000
Clifford G. Adlerz	75,000	140,000	215,000
T. Devin O'Reilly (2)	—	—	—
Andrew T. Kaplan (2)	—	—	—
Patricia A. Maryland, Dr.PH (3)	56,250	140,000	196,250
Blair E. Hendrix (2)	—	—	—

SEC Form DEF 14A filed by Surgery Partners Inc.